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Abstract The expression of the receptor for the urokinase-type
plasminogen activator (uPAR) can be regulated by several
hormones, cytokines, tumor promoters, etc. Recently, it has been
reported that uPAR is capable of transducing signals, even
though it is lacking a transmembrane domain and a cytoplas-
matic tail. We now report that uPAR cell surface expression can
be positively regulated by its ligand, uPA, in thyroid cells. The
effect of uPA is independent of its proteolytic activity, since
inactivated uPA or its aminoterminal fragment have the same
effects of the active enzyme. The increase of uPAR on the cell
surface correlates with an increase of specific uPAR mRNA.
Finally, uPA up-regulates uPAR expression also in other cell
lines of different type and origin, thus suggesting that the
regulatory role of uPA on uPAR expression is not restricted to
thyroid cells, but it occurs in different tissues, both normal and
tumoral. ß 2000 Federation of European Biochemical Socie-
ties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The urokinase-type plasminogen activator (uPA) and its
cellular receptor (uPAR) belong to one of the most e⁄cient
proteolytic systems active in the extracellular environment.
Active uPA, by converting plasminogen into plasmin, pro-
motes a proteolytic cascade which can lead to the degradation
of most extracellular matrix (ECM) proteins [1,2]. The pres-
ence of uPAR highly potentiates cell surface proteolytic activ-
ity mediated by uPA [3].
uPAR plays a prominent role also in cell adhesion [4]. In
fact, the receptor binds vitronectin (VTN), a speci¢c compo-
nent of the ECM [5], and interacts with integrins of the L1,
L2, L3 and L5 families [6^8], often modifying their substrate
speci¢city [6].
uPA is a two-chain serine protease; the uPAR-binding re-
gion of uPA resides in the aminoterminal region of the A
chain, whereas the catalytic domain is contained in the B
chain [1,2]. Therefore, uPA retains its proteolytic activity
even after binding its receptor. In recent years, it has been
clearly shown that uPA, upon binding uPAR and indepen-
dently of its proteolytic activity, can activate cell-signalling
pathways involved in cell adhesion, cell migration and chemo-
taxis [4].
uPAR is a heavily glycosylated single-chain protein with an
molecular weight (MW) of 45^60 kDa. It is anchored to the
cell surface by a GPI tail [9] and therefore lacks a transmem-
brane domain and a cytosolic tail, but it is capable of trans-
mitting extracellular signals inside the cell, probably by asso-
ciation with other cell membrane molecules, such as integrins
[6], caveolin [10] or unidenti¢ed adapters [11].
uPAR expression can be regulated by tumor promoters,
cytokines, hormones and growth factors, both at transcrip-
tional and post-transcriptional levels [12]. We have previously
shown that uPA, upon binding uPAR, increases thyroid cell
surface expression of Kv and L3 integrins, which form recep-
tors for VTN [13]. In this report we show that uPA can
regulate also the cell surface expression of its receptor and
investigate the mechanism underlying this regulatory e¡ect.
2. Materials and methods
2.1. Reagents
Mouse monoclonal antibodies R4 were kindly provided by Dr. G.
Hoyer-Hansen (Finsen Laboratory, Copenhagen, Denmark). Horse-
radish peroxidase-conjugated anti-mouse and anti-rabbit IgG were
from Bio-Rad (Richmond, CO, USA), FITC-labelled anti-mouse
IgG from Jackson (West Grove, PA, USA) and polyclonal anti-actin
antibody from Sigma (St. Louis, MO, USA). Enhanced chemolumi-
nescence (ECL) detection kit was from Amersham International
(Amersham, England); Trizol reagent and Superscript II (RNase H
reverse transcriptase) from Life Technologies (Gaithersburg, MD,
USA). Polyvinylidene £uoride (PVDF) ¢lters were from Millipore
(Windsor, MA, USA) and the PCR kit from Perkin-Elmer (Branch-
burg, NJ, USA).
2.2. Cell culture
TAD-2 cell line was derived from human fetal thyroid cells [14],
ARO cells from anaplastic thyroid carcinoma [14], WRO and NPA
from follicular and papillary thyroid carcinoma, respectively [15].
These cell lines were cultured in RPMI 1640 medium (Flow, McLean,
VA, USA) supplemented with 10% fetal calf serum (Gibco). Melano-
ma A2058 cells, 293 human kidney cells and a primary culture of
human ¢broblasts were grown in DMEM supplemented with 10%
fetal calf serum.
2.3. Cell stripping
Acid treatment of cells was performed as previously described [16],
in order to strip surface-bound endogenous uPA.
2.4. Western blot
Cells were lysed in 1% Triton X-100 in PBS and the protein content
was measured by a colorimetric assay (Bio-Rad, Richmond, CO,
USA). 50 Wg of total protein was electrophoresed on a 9% SDS^
PAGE and transferred onto a PVDF membrane. The membrane
was blocked with 5% non-fat dry milk, and probed with R4 anti-
uPAR antibody, at a concentration of 1 Wg/ml. Finally, washed ¢lters
were incubated with horseradish peroxidase-conjugated anti-mouse
antibody and detected by ECL. Some ¢lters were washed and re-
probed with rabbit anti-actin antibodies (1 Wg/ml).
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2.5. Immuno£uorescence
Cells were washed and harvested by PBS^EDTA 10 mM. After
three washes in Ca2Mg2-containing PBS, 5U105 cells were incu-
bated with 1 Wg/ml of R4 anti-uPAR monoclonal antibody for 1 h at
4‡C. Puri¢ed mouse immunoglobulins were used as a negative control.
Cells were then washed in PBS^0.1% BSA and incubated with an
FITC-labelled rabbit anti-mouse IgG for 30 min at 4‡C. Finally, cells
were washed and analyzed by £ow cytometry using a FACScan (Bec-
ton Dickinson, Mountain View, CA, USA).
2.6. Reverse polymerase chain reaction
Total cellular RNA was isolated by lysing cells in Trizol solution.
RNA was precipitated and quantitated by spectroscopy. 5 Wg of total
RNA was reversely transcribed with random hexamer primers and
200 U of RNase H reverse transcriptase. 1 Wl of reversely transcribed
DNA was then ampli¢ed using uPAR speci¢c 5P sense (CTG CGG
TGC ATG CAG TGT AAG) and 3P antisense (GGT CCA GAG
GAG AGT GCC TCC) 21-mer cDNA primers or GAPDH speci¢c
5P sense (TTC ACC ACC ATG GAG AAG GCT) and 3P antisense
(ACA GCC TTG GCA GCA CCA GT) 20-mer cDNA primers as a
control. PCR was performed for 25 cycles at 63‡C in a thermocycler,
and the reaction products were analyzed by electrophoresis in 1%
agarose gel containing ethidium bromide, followed by photography
under ultraviolet illumination.
3. Results
3.1. uPA increases uPAR antigen in thyroid cells
TAD-2 cells express large amounts of uPAR and can spe-
ci¢cally bind uPA [17]. We previously reported that these cells
express also a truncated form of the receptor, which lacks the
uPA-binding domain and shows an MW of 35 kDa [17].
We investigated if uPA is able to a¡ect uPAR expression in
these cells.
TAD-2 cells were stripped of endogenous uPA by acid
treatment, incubated with or without 50 nM uPA for 2 h
and 24 h in the absence of serum and ¢nally lysed. The 2 h
incubation was preceded by a 22 h serum starvation in order
to equalize the basal expression of uPAR in both treatments.
Western blot analysis of total lysates with R4 anti-uPAR
monoclonal antibody showed that 2 h of uPA treatment
(Fig. 1, lane 2) slightly increased uPAR expression (50 and
35 kDa MW) as compared to the untreated control (Fig. 1,
lane 1), whereas 24 h of uPA treatment (Fig. 1, lane 4)
strongly increased uPAR expression as compared to the con-
trol (Fig. 1, lane 3). In lane 4, the ratio between the 50 and
35 kDa forms is di¡erent compared to the other lanes prob-
ably because the longer incubation with uPA can generate the
Fig. 1. uPA increases uPAR expression in thyroid cells. TAD-2 cells
were stripped of endogenous uPA by acid treatment, incubated with
(lanes 2, 4) or without (lanes 1, 3) 50 nM uPA for 2 h (lanes 1, 2)
or 24 h (lanes 3, 4), lysed and analyzed by Western blot with R4
anti-uPAR monoclonal antibody.
Fig. 2. uPA increases uPAR cell surface expression. Acid-treated
TAD-2 cells were incubated for 24 h with 5 nM (c) or 50 nM (d)
uPA or without uPA (b). Cells were then harvested by EDTA, incu-
bated with R4 anti-uPAR monoclonal antibody (b, c, d) or with
non-immune serum as a control (a). Cells were ¢nally incubated
with FITC-labelled rabbit anti-mouse IgG and analyzed by £ow
cytometry. Mean £uorescence intensity values = a: 14.09; b: 29.72;
c: 85.54; d: 84.39.
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truncated form of uPAR by proteolytic cleavage. This experi-
ment was performed three times in duplicate with similar re-
sults.
We then investigated whether the observed increase of
uPAR in total cell lysates re£ected a higher cell surface ex-
pression of the receptor. TAD-2 cells treated with 5 or 50 nM
uPA for 24 h were harvested by 10 mM PBS^EDTA, incu-
bated with R4 anti-uPAR monoclonal antibody and analyzed
by £ow cytometry. Cell surface expression of uPAR was
strongly up-modulated (about 3-fold) after 24 h of uPA treat-
ment (Fig. 2c,d), as compared to the untreated control (Fig.
2b). No di¡erences were observed between 5 and 50 nM uPA
treatments (Fig. 2c,d). These data showed that uPA increases
uPAR expression on the cell surface.
It should be noted that TAD-2 cells produce moderate
amounts of PAI-1 [17] which can lead to the internalization
of the uPA^uPAR complex. Therefore it is possible that the
observed increase in the uPAR level induced by uPA was
underestimated.
3.2. uPA-mediated uPAR increase is independent of uPA
proteolytic activity
The e¡ect of uPA on uPAR expression could be due to the
proteolytic activity of the enzyme or to its interaction with the
receptor. uPAR expression was then investigated after incu-
bation of TAD-2 cells with uPA inactivated by DFP treat-
ment or with the aminoterminal fragment of uPA (ATF),
corresponding to the uPAR-binding region of uPA.
TAD-2 cells were stripped of endogenous uPA by acid
treatment, incubated for 24 h with medium (Fig. 3, lane 1),
5 or 50 nM DFP-inactivated uPA (Fig. 3, lanes 2, 3 respec-
tively), 5 nM ATF (Fig. 3, lane 4), 50 nM uPA, as a positive
control (Fig. 3, lane 5) and ¢nally lysed. Western blot analysis
of total lysates with R4 anti-uPAR monoclonal antibody
showed that both DFP-inactivated uPA (Fig. 3, lanes 2, 3)
and ATF (Fig. 3, lane 4) are capable of increasing uPAR
expression as compared to the untreated control (Fig. 3,
lane 1). Same results were obtained in two di¡erent experi-
ments, performed in duplicate.
These results clearly show that the increase of uPAR ex-
pression depends on the interaction of uPA with its receptor,
since it occurs even in the absence of any uPA proteolytic
activity.
3.3. uPA increases uPAR mRNA in thyroid cells
We then investigated by RT-PCR if the observed increase
of uPAR expression was related to an increase of uPAR
mRNA (Fig. 4). TAD-2 cells were incubated with (Fig. 4,
lane 2) or without (Fig. 4, lane 1) 5 nM DFP^uPA for 24
h. Total RNA was prepared, reverse transcribed and ampli¢ed
by 25 cycles PCR in the presence of primers for uPAR or for
GAPDH as a control (Fig. 4, lanes 1, 2). Bu¡er (Fig. 4, lane
3) or uPAR cDNA (Fig. 4, lane 4) were ampli¢ed as negative
and positive control, respectively. The analysis of PCR prod-
ucts by agarose gel showed the increase in uPAR mRNA in
cells treated with DFP^uPA (Fig. 4, lane 2) as compared to
untreated cells (Fig. 4, lane 1) in which basal uPAR mRNA
was below the threshold of detection.
3.4. uPAR increase mediated by uPA occurs in di¡erent cell
types
uPA e¡ect was also studied in tumor and normal cell lines
of di¡erent origin in order to investigate if it was restricted
only to TAD-2 cells. TAD-2 thyroid cells (Fig. 5, lanes 1, 2),
WRO follicular thyroid carcinoma cells (Fig. 5, lanes 3, 4),
Fig. 3. uPA-mediated uPAR increase is independent of uPA proteo-
lytic activity. TAD-2 cells were stripped of endogenous uPA by acid
treatment and incubated for 24 h with medium (lane 1), 5 or 50 nM
DFP^uPA (lanes 2, 3 respectively), 5 nM ATF (lane 4), 50 nM
uPA (lane 5). Cells were then lysed and analyzed by Western blot
with R4 anti-uPAR monoclonal antibody. Bottom panel: same ¢lter
hybridized with anti-actin polyclonal antibodies as a control for
protein loading.
Fig. 4. uPA increases uPAR mRNA in thyroid cells. TAD-2 cells
were incubated with (lane 1) or without (lane 2) 5 nM DFP^uPA
for 24 h. PCR was performed with 1 Wl of reverse transcribed
cDNA (lanes 1, 2) or without DNA as negative control (lane 3) in
the presence of primers for uPAR or for GAPDH. 10 ng of uPAR
cDNA was ampli¢ed as a positive control (lane 4). PCR products
were analyzed by 1% agarose gel containing ethidium bromide, fol-
lowed by photography under ultraviolet illumination.
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NPA papillary thyroid carcinoma cells (Fig. 5, lanes 5, 6),
A2058 melanoma cells (Fig. 5, lanes 7, 8), HeLa epidermoid
carcinoma cells (Fig. 5, lanes 9, 10) and primary cultures of
¢broblasts (Fig. 5, lanes 11, 12) were treated with (Fig. 5,
lanes 2, 4, 6, 8, 10, 12) or without (Fig. 5, lanes 1, 3, 5, 7,
9, 11) 5 nM DFP^uPA for 24 h, lysed and analyzed by West-
ern blot with anti-uPAR antibodies. uPA treatment increased
uPAR expression in all the di¡erent cell lines, independently
on their normal or tumor origin.
uPAR-negative 293 kidney cells [6] cannot bind the enzyme
and, as expected, were not sensitive to uPA e¡ect (Fig. 5,
lanes 13, 14).
4. Discussion
uPAR and its ligand uPA have been implicated in several
pathological and physiological processes which require cell
migration, in particular tumor cell invasion and metastasis.
In fact, uPAR and uPA play a central role in cell-associated
proteolysis [3] and in cell adhesion [4], which are required for
cell migration. Enhanced levels of uPAR have been described
in several types of tumor, both on the cell surface and in
plasma [3,18^20]. It is to be thus expected that the expression
of uPAR is strictly controlled. In this report we investigated if
uPAR could be regulated by its own ligand. We showed that
indeed the interaction of uPA with uPAR up-regulates the
expression of the receptor. The active enzyme is also able to
cleave its receptor, thus removing the uPA-binding domain
[21]; this proteolytic activity could explain previous results
showing a reduction in the speci¢c binding of DFP^uPA in
cells pre-treated with active uPA [22,23]. Therefore, uPA can
regulate both uPAR expression and uPAR functions [24] and
its ¢nal e¡ect depends on the balance between these two reg-
ulatory activities.
It has been reported that uPAR expression can be e⁄ciently
regulated: the high lability of uPAR mRNA allows a rapid
down-regulation of protein synthesis and provides an e⁄cient
mechanism for transient expression [25]. uPA, which ‘in vivo’
could be provided by tumor-in¢ltrating stromal cells [3], coun-
teracts this regulation, thus promoting the overexpression of
uPAR observed, for instance, in several types of tumor.
Enhanced adherence to VTN has been associated to in-
creased invasiveness of tumor cells [26]. uPAR can act as
VTN receptor [5] ; its a⁄nity for VTN is enhanced after bind-
ing uPA [27]. uPAR and integrinic receptors for VTN can be
co-regulated [28] and we have previously reported that uPA,
in thyroid cells, increases the expression of integrinic receptors
for VTN [13]. It is then possible that uPA, upon binding to
uPAR, modulates the expression of integrinic and non-integ-
rinic receptors for VTN, thus playing a prominent role in
regulating cell adhesion to VTN.
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